Buzz: This little biotech has so much going against it, somebody is going to want to buy it. Right?
It’s the week after JPMorgan was dominated by M&A news, so let’s get started on the rest of the year by talking about which biotechs are being groomed for an acquisition.
Company number 1 fits the bill perfectly.
Alder $ALDR has a lot going against it. The biotech has secured a last-place finish for itself among the CGRP migraine players after stumbling over its development schedule for eptinezumab and executing a management shakeup. It’s essentially a one-drug company, with a tiny staff going up against marketing giants like Amgen and Novartis and Eli Lilly and Teva. Even if it wins an approval for its late-stage drug and goes on to launch in 2020, how does it expect to sell the therapy?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.